Article info
PDFPapers
Neuroethics
Neuroenhancers, addiction and research ethics
- Correspondence to Dr David Martin Shaw, Institute for Biomedical Ethics, University of Basel, Missionsstrasse 24, CH-4055 Basel, Basel-Stadt, Switzerland; davidmartinshaw{at}gmail.com
Citation
Neuroenhancers, addiction and research ethics
Publication history
- Received March 2, 2012
- Revised June 27, 2012
- Accepted July 21, 2012
- First published August 11, 2012.
Online issue publication
April 27, 2016
Article Versions
- Previous version (27 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Cognitive neuroenhancement: false assumptions in the ethical debate
- True and false concerns about neuroenhancement: a response to ‘Neuroenhancers, addiction and research ethics’, by D M Shaw
- Sugar addiction: is it real? A narrative review
- Neuroenhancing public health
- Neuropsychiatry of the basal ganglia
- Extrastriatal dopaminergic changes in Parkinson’s disease patients with impulse control disorders
- Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology
- Medical use and combination drug therapy among US adult users of central nervous system stimulants: a cross-sectional analysis
- The use of methylphenidate among students: the future of enhancement?
- Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management